Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Lymphoid 4Genitourinary 4Other hematologic neoplasm 3Sarcoma 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Laryngeal Neoplasms 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × gossypol acetic acid × Head & Neck × Clear all
NCT01633541 2023-07-20

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

University of Michigan Rogel Cancer Center

Phase 2 Completed
55 enrolled 15 charts
Head & Neck

Laryngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡